Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.